Articles tagged with Cancer Medication
Researchers found that PLX3397, a tyrosine kinase inhibitor, induced partial responses and stable disease in 79% of evaluable patients with advanced PVNS. The drug demonstrated significant tumor size reduction and minimal side effects.
A team of USC and NYU researchers has developed a small molecule that interferes with cancer progression by mimicking the surface topography of one protein, tricking another into binding with it. This stops an aberrant gene expression contributing to cancer growth with minimal side effects.
The University of Chicago Medicine Comprehensive Cancer Center has been awarded a five-year, $3.9-million grant to serve as a Lead Academic Participating Site for the National Clinical Trials Network. The new network aims to improve cancer clinical trials' speed and efficiency.
A new study reveals that US cervical cancer rates are higher than previously believed, particularly among women over 65 and African-American women. The study found an age-standardized rate of 18.6 cases of cervical cancer per 100,000 women, with incidence increasing steadily with age.
Researchers developed a novel anti-cancer drug delivery method using lipid-based nanocapsules to deliver drugs directly to cancer cells. The technique triggers the release of the drug, leading to cell death in breast cancer tumors. This efficient and fast-acting approach may improve treatment outcomes for cancer patients.
Researchers at Dartmouth's Norris Cotton Cancer Center have discovered a new epigenetic mechanism that distinguishes normal blood stem cells from blood cancers. This finding holds promise for developing targeted treatments that preserve healthy stem cells while killing leukemia cells.
Researchers develop nanoparticles that release two chemotherapy drugs, erlotinib and doxorubicin, at staggered times to weaken tumor cells' defenses before delivering DNA-damage. This approach dramatically shrinks lung and breast tumors in mice, including aggressive triple-negative breast cancer cells.
Using a novel bioinformatics approach, researchers have found that the approved antimicrobial drug pentamidine may help treat advanced kidney cancer. The study identified gene expression patterns that suggest an antimicrobial may be effective against clear cell renal cancer, a common and highly malignant subtype of kidney cancer.
Two UT Southwestern doctors have received grants to test the effectiveness of itraconazole on lung cancer pathways and growth. The researchers aim to disrupt communication between tumor cells and their surrounding environment, slowing cancer growth.
Researchers discovered microRNA-10a regulates human airway smooth muscle cell growth and inhibits PI3 kinase, a master regulator of cell proliferation. This finding offers a new approach to treating both asthma-induced muscle thickening and cancerous tumor growth.
Researchers have identified a key chemical that can repair damaged cell nuclei, a breakthrough in treating Hutchinson-Gilford Progeria Syndrome (HGPS), a rare and devastating ageing disease. The compound, Remodelin, also shows promise in reducing DNA damage and improving cellular health.
A new study reveals the link between obesity and increased risk of myeloma, a cancer of plasma cells. The researchers found that adiponectin, a protective protein, can be used to suppress fatty acid production in myeloma cells, leading to their demise.
Researchers at Georgetown University Medical Center have identified Yes-associated protein (Yes) as the critical switch that promotes cancer growth and progression in pancreatic ductal adenocarcinoma (PDAC). Inhibiting Yes completely shuts down further growth of pancreatic cancer, offering a promising therapeutic target.
Advances in biological imaging enable scientists to identify the most promising new drugs and rule out those unlikely to work, potentially improving the success rate of cancer medicines. Researchers are using this approach to streamline the drug discovery process, reducing costs and side effects.
A study of 67 transplant patients found those with naturally high levels of HLA-G dimer, a powerful immune molecule package, had the lowest risk of rejecting their transplanted kidney. High HLA-G levels also correlated with lower inflammation and higher expression of HLA-G receptors.
Biologists have identified a crucial outer shield on T-type channels that influences the electrochemical signaling of heart and brain cells. This finding holds promise for developing new drugs to treat epilepsy, cardiovascular disease, and cancer by targeting this regulator.
Researchers at Drexel University have created a method for 3D printing living cancer tumors using cervical cancer cells and hydrogel substances. This breakthrough technology allows for more accurate modeling of tumor behavior and response to treatment, potentially leading to new paradigms for cancer research and individual therapies.
Researchers have uncovered how cells block mutation-causing activity of junk DNA, a process involving an enzyme called APOBEC3A. This defense mechanism may help explain a long-standing mystery and has potential implications for cancer treatment.
Moffitt Cancer Center's phase 3 study shows CPX-351 leads to higher remission rates compared to standard options in AML, offering a new game-changer for treatment. The innovative drug combination works by maintaining an optimal ratio of cytarabine and daunorubicin inside lipid vesicles.
Researchers at National University of Singapore identify cancer-specific stem cell causing gastric cancer, opening possibility of developing new drugs to treat this disease. They discovered a cancer-specific variant of a cell surface protein, CD44v8-10, marks gastric cancer stem cells but not normal cells.
Researchers at Harvard's Wyss Institute have successfully created DNA nanodevices that can survive the body's immune defenses long enough to perform diagnostic or therapeutic tasks. The devices use a virus-like cloaking strategy to evade the immune system and deliver drugs directly to diseased tissues.
Researchers found that false-positive mammograms have a temporary and limited impact on women's overall health and well-being. The study also showed that women who experience a false positive may actually be more likely to use breast cancer screening in the future.
Researchers at the University of Pittsburgh discovered a malfunction in the molecular 'proofreading' machinery that repairs DNA damage caused by ultraviolet (UV) light. The protein UV-DDB makes stops along the DNA strand and transiently attaches to it, causing a proofreading change in its conformation, preventing repair in damaged areas.
Researchers have discovered a new role for Cullin-5 in killing cancer cells by targeting proteins that drive cell division. The study suggests a possible test to identify responsive patients and develop more effective drugs.
Scientists have identified a molecule called CD61 on the surface of drug-resistant tumors that induces tumor metastasis by enhancing cancer cell properties. The findings suggest that existing drugs can exploit this pathway to reverse drug resistance and re-sensitize tumors.
A pioneering clinical trial will test multiple drugs simultaneously in patients with advanced lung cancer based on their genetic profile. The 'National Lung Matrix' trial aims to provide more personalized treatment options for cancer patients.
Researchers discovered that cancer drugs can eliminate neural inflammation associated with dementia-linked diseases by eradicating microglia, the primary immune cells of the brain. The study found that these cells exacerbate many neural diseases, including Alzheimer's and Parkinson's, as well as brain injury.
Researchers have created nanoparticles that can deliver three or more different chemotherapy drugs to cancer cells, offering new hope for more effective treatments. The particles are designed to release the drugs in response to specific triggering mechanisms, reducing side effects and increasing efficacy.
A 20-year study confirms that moderate to severe obstructive sleep apnea is independently associated with an increased risk of stroke, cancer, and death. The study found that people with severe sleep apnea were four times more likely to die and nearly four times more likely to have a stroke.
Singlet oxygen modifies target molecules through precise location and monitoring its effects on HCN channels in open and closed states. The findings introduce a method for further exploration of singlet oxygen's role in biological processes, including memory, heart rate, pain sensation, and cancer development.
University of Delaware researchers show that routine procedures in handling and processing nanocarrier solutions can alter their size and shape, affecting targeted drug delivery to cancer cells. The study's findings have significant implications for the production, storage, and use of nano-based drug delivery systems.
Researchers identified a new drug, AMPI-109, effective against triple-negative breast cancer by targeting the PTP4A3 oncogene. The study also provided molecular insights into the disease's biology.
Researchers at Johns Hopkins Kimmel Cancer Center have identified SGK1 enzyme as a potential target for treating asthma and boosting the effects of certain cancer therapies. The enzyme's role in regulating immune system T cells suggests that blocking it could inhibit asthma symptoms and enhance cancer treatment.
A team of researchers created a 3D model of cervical cancer cells using 3D printing, mimicking the complex environment of a tumor. The model showed higher proliferation rates and resistance to anti-cancer drugs compared to traditional 2D models.
Researchers at Duke University Medical Center found that cancers with a BRAF gene mutation require copper for tumor growth, leading to potential new treatments using copper-reducing drugs. The study provides hope for patients with melanoma and other BRAF-driven cancers.
A new experimental compound called TTT-3002 has been identified as a potent inhibitor of genetic mutations in cancer cells that cause some forms of treatment-resistant leukemia. In mouse models, the drug eliminated leukemia cells within 10 days and showed activity against FLT3-mutated cells.
A phase II trial of efatutazone with erlotinib failed to improve efficacy in patients with refractory non-small cell lung cancer, but researchers hope to refine future treatments by identifying the right biomarker for individual patients. The study found that fluid retention was a key factor contributing to the lack of success.
Researchers at UC Davis have identified the atomic structure of kinesin-5, a protein essential for mitosis in virtually all eukaryotic cells. The newly discovered structure reveals unique pockets that could be exploited as targets for new anti-cancer drugs.
A Western University study has discovered a unique population of microbes in the female breast associated with cancer risk. The research found that certain types of bacteria, including Proteobacteria, were present in and beside tumors.
A national survey of over 2,500 teens and young adults found a strong association between liking music with alcohol brand references and increased binge drinking. The study suggests that policy interventions targeting these references could help reduce teen alcohol consumption.
Researchers at the University of Southampton found that a combination of cetuximab and chemotherapy was not effective in treating advanced bowel cancer that had spread to the liver. The study, published in The Lancet Oncology, suggests that this treatment approach may even accelerate cancer progression in some cases.
The I-SPY 2 trial found that neratinib-based treatment improved outcomes for women with newly diagnosed, high-risk breast cancer. The adaptive randomization algorithm successfully identified patient subgroups likely to benefit from the regimen.
A new study from Ohio State University found that the NRAS gene produces five different variants, rather than just one original form, which may help improve cancer treatment. The discovery of these variants could lead to the development of more effective drugs targeting the NRAS pathway.
A recent study published in the Proceedings of the National Academy of Sciences found that the intensity difference between an immune response that stimulates cancer and one that kills it may be minimal. This discovery challenges long-held assumptions about the role of the immune system in preventing and killing cancers.
Researchers develop a new strategy to kill bladder cancer cells by attaching gold nanorods to EGFR proteins, which are overexpressed on these cells. The application of low-intensity laser heat the nanorods, killing the cancer cells without harming healthy tissue.
Researchers from the University of California - San Francisco, led by Margaret Tempero, are part of a national 'dream team' working to accelerate treatment and discoveries for pancreatic cancer. The team aims to turn the deadly disease into a treatable one through targeted approaches and collaborative research.
Researchers have found several molecular alterations that drive the cancer, including mutations and epigenetic changes. The study identifies potential new targets for drug treatments, including existing drugs that could block specific mutations.
A new study by Dartmouth researchers found that young people are increasingly influenced by tobacco marketing, with exposure to coupons and websites associated with increased smoking rates. Black and Hispanic youth are disproportionately affected.
Researchers found that recurrent cancers have unique gene mutations sensitive to dasatinib, a promising new treatment option for recurrent head and neck cancers.
Researchers at UPCI discovered that a subset of patients with lobular carcinoma receive less benefit from adjuvant tamoxifen, indicating potential targets for drug therapy. The study suggests a unique signaling pathway regulated by estrogen in lobular carcinoma cells may be exploited in future clinical trials.
Researchers at the University of Pittsburgh Cancer Institute have discovered a combination therapy that overcomes tumor cell resistance to cisplatin, a widely used cancer drug. The therapy, which involves combining a cell replication blocker with cisplatin, induces rapid and synergistic cell death in resistant tumor cells.
Researchers have developed a new drug delivery method that targets cancer cells using nanoballoons encapsulating anti-cancer drugs. The nanoballoons release the drugs when struck by a red laser, limiting interactions with healthy bodily systems and reducing side effects.
SRPK1 acts as a tumor suppressor when abundant and promotes cancer when scarce, according to researchers at UC San Diego. This unexpected dual role is crucial for understanding tumorigenesis in humans.
A study published in Cancer Epidemiology, Biomarkers & Prevention found that women who took clomiphene citrate or gonadotropins for fertility treatment did not have an increased risk of breast cancer over 30 years. However, a small number of women had a higher risk after multiple cycles of these medications.
Physician Emil J Freireich and scientist Jim Allison have been elected as fellows of the American Association for Cancer Research Academy, known for their contributions to cancer treatment and immunotherapy. Their work has driven significant innovation and progress against cancer, leading to improved survival rates for patients.
Researchers at Dartmouth developed a more accurate and safer treatment for pancreatic cancer by analyzing pre-treatment CT scans. The study found that blood volume in tumors is a key predictor of treatment response, making PDT easier, faster, and more effective.
Professor Jerry Adams has been elected a fellow of the American Association for Cancer Research (AACR) Academy for his outstanding contributions to understanding genes that provoke cancer and control cell death. His research has implicated key drivers of cancer development and revealed their role in cancer drug resistance.
A new study found that certain genetic variants, such as ALDH2 and VCAM1, can predict bladder cancer recurrence in patients. These variants can help identify high-risk patients who require more frequent screenings and aggressive treatment, improving quality of life for all bladder cancer patients.
Researchers discovered several novel genetic defects that cause oesophageal squamous carcinoma, a type of aggressive cancer prevalent in Singapore and Southeast Asia. The study provides insight into the molecular basis of this disease and potential new therapies for treatment.
Researchers identified two adult cancer drugs, pemetrexed and gemcitabine, with potential to improve treatment of high-risk childhood brain tumors. The combination doubled life expectancy of mice with human group 3 medulloblastoma, a subtype with the worst prognosis.